Miacalcic (Calcitonin Salmon, Synthetic)

Calcitonin salmon binds to specific calcitonin receptors on osteoclasts, the cells responsible for bone breakdown. This binding blocks osteoclast activity, decreasing bone resorption, and also reduces renal reabsorption of calcium, promoting its excretion in urine, which together lower blood calcium concentrations.

The exact dosage and frequency of Miacalcic are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal calcium control while minimizing adverse effects.

The pregnancy category for calcitonin salmon is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful consultation with a healthcare provider.

To place an order, submit an enquiry on the Miacalcic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Miacalcic (calcitonin) acts by directly inhibiting osteoclasts and increasing renal calcium excretion, offering rapid calcium reduction. Compared with bisphosphonates, which bind bone mineral and have a longer half‑life, calcitonin provides a shorter‑acting option and may be preferred when rapid calcium lowering is needed or when bisphosphonate tolerance is an issue.

Miacalcic must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Miacalcic is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and physician preference. The injection site should be rotated for repeated doses, and the solution must be inspected for particulate matter before administration.

The most critical adverse events include severe allergic reactions such as anaphylaxis, marked hypocalcemia that can cause muscle cramps or tetany, rare cases of osteosarcoma with long‑term use, and sudden hypotension especially after rapid intravenous injection. Patients should be monitored closely for these signs.

Miacalcic is contraindicated in individuals with known hypersensitivity to salmon calcitonin or any excipients in the formulation. It should also be avoided in patients with severe renal impairment without close monitoring, and in those who have experienced severe reactions to other calcitonin preparations.